Cristi Radford, MS, CGC

Authored Items
“Newer” Ovarian Cancer Genes and Option of Risk-Reducing Salpingo-Oophorectomy
Cristi Radford, MS, CGC
Online First in Genetic Counseling, Online First
T-DM1 in Metastatic Breast Cancer
Cristi Radford, MS, CGC
TOP - August 2012, Vol 5, No 5 in Breast Cancer
Exploring the Drug Shortage Crisis
Cristi Radford, MS, CGC
TOP - August 2012, Vol 5, No 5 in Drug Updates
Pharmacists Can Enhance Compliance With Oral Medications
Cristi Radford, MS, CGC
TOP - June 2012, Vol 5, No 4 in Best Practices
Abstracts of Interest From the 2012 American Society of Clinical Oncology Annual Meeting
Cristi Radford, MS, CGC
TOP - June 2012, Vol 5, No 4 in Conference Correspondent
Payer Trends in Oncology: Challenges and Solutions
Cristi Radford, MS, CGC
TOP - Special Issue May 2012, Vol 5, No 3 in Conference Correspondent
What Pharmacists Need to Know About 7 New Agents
Cristi Radford, MS, CGC
TOP - Special Issue May 2012, Vol 5, No 3 in Drug Updates
Many Febrile Neutropenia Patients Can Be Treated at Home
Cristi Radford, MS, CGC
TOP - April 2012, Vol 5, No 2 in Supportive Care
What’s New in Antiemetic Control?
Cristi Radford, MS, CGC
TOP - April 2012, Vol 5, No 2 in Supportive Care
Eribulin Associated With Less Neuropathy Than Ixabepilone in a Prospective, Randomized Study
Cristi Radford, MS, CGC
TOP - February 2012, Vol 5, No 1 in Breast Cancer
New Bone-Targeting Compound Improves Survival in Metastatic Prostate Cancer
Cristi Radford, MS, CGC
TOP - December 2011, Vol 4, No 8 in Genitourinary Cancers
Positive Data Continue to Accrue for Crizotinib in ALK-Positive NSCLC
Cristi Radford, MS, CGC
TOP - December 2011, Vol 4, No 8 in Lung Cancer
Chemoprevention in Breast Cancer: Which Agents for Which Patients?
Cristi Radford, MS, CGC
TOP - October 2011 Vol 4, No 7 in Conference Correspondent
A Wealth of Targets Identified in Colorectal Cancer
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 in Colorectal Cancer
Upper GI Cancers: Are We Getting Value for the Money?
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 in Gastrointestinal Cancers
Optimal Length of Treatment of Non-Hodgkin Lymphoma Debated
Cristi Radford, MS, CGC
TOP - August 2011 Vol 4, No 5 in Conference Correspondent, Hematologic Cancers
Drug Exposure, Response Rates Associated with Higher Doses of Melphalan
Cristi Radford, MS, CGC
Web Exclusives in Drug Therapies
Preoperative Treatment with Anti-HER2 Agents Yields Benefits in Key Studies
Cristi Radford, MS, CGC
TOP - February 2011, Vol 4, No 1
Preoperative Anti-HER2 Agents Yield Benefits
Cristi Radford, MS, CGC
Web Exclusives
Estrogen Alone Poses No Increased Breast Cancer Risk
Cristi Radford, MS, CGC
Web Exclusives
For Breakthrough Cancer Pain, Fentanyl Nasal Spray Easily Titratable and Effective
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8
Sex and the Cancer Patient: Still a Problem with Targeted Agents
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8
Prolonging Chemotherapy in Metastatic Breast Cancer Improves Survival
Cristi Radford, MS, CGC
TOP - December 2010, Vol 3, No 8
Novel Agent Has Striking Activity in Lung Cancer Subset
Cristi Radford, MS, CGC
Web Exclusives
Last modified: December 11, 2015